Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01 +1.0%	$0.01	$0.01 ▼ $0.02	$1.19M	-1	467,125 shs	122,859 shs
HEPA Hepion Pharmaceuticals	$0.04 +0.5%	$0.29	$0.04 ▼ $66.00	$443K	1.9	1.30 million shs	99,580 shs
SXTC China SXT Pharmaceuticals	$1.30 -1.5%	$2.01	$0.95 ▼ $11.92	$20.58M	1.24	2.60 million shs	157,247 shs
TFFP TFF Pharmaceuticals	$0.07	$0.06	$0.06 ▼ $3.23	$289K	1.07	794,942 shs	N/A

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	-1.00%	0.00%	+10.00%	+16.47%	-29.94%
HEPA Hepion Pharmaceuticals	-38.15%	-47.52%	-85.87%	-99.21%	-99.94%
SXTC China SXT Pharmaceuticals	-4.34%	-14.84%	-42.11%	-71.86%	-84.29%
TFFP TFF Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-96.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVFM Evofem Biosciences	1.0885 of 5 stars	0.0	5.0	0.0	4.8	0.6	0.0	0.0
HEPA Hepion Pharmaceuticals	0.55 of 5 stars	0.0	5.0	0.0	0.0	0.6	0.0	0.6
SXTC China SXT Pharmaceuticals	1.3306 of 5 stars	0.0	5.0	0.0	0.0	3.6	0.0	0.6
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVFM Evofem Biosciences	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.29 per share	N/A
SXTC China SXT Pharmaceuticals	$1.82M	11.32	N/A	N/A	$30.46 per share	0.04
TFFP TFF Pharmaceuticals	-$70.98K	-4.07	N/A	N/A	$4.04 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVFM Evofem Biosciences	$52.98M	-$0.05	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
HEPA Hepion Pharmaceuticals	-$48.93M	-$219.00	N/A	∞	N/A	N/A	-812.56%	-207.31%	8/11/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	-$21.24M	-$6.44	N/A	∞	N/A	-1,596.64%	-310.17%	-196.06%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
HEPA Hepion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVFM Evofem Biosciences	N/A	0.11	0.09
HEPA Hepion Pharmaceuticals	N/A	1.30	1.30
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	0.89	0.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVFM Evofem Biosciences	0.22%
HEPA Hepion Pharmaceuticals	17.24%
SXTC China SXT Pharmaceuticals	5.02%
TFFP TFF Pharmaceuticals	15.25%

Insider Ownership

Company	Insider Ownership
EVFM Evofem Biosciences	0.21%
HEPA Hepion Pharmaceuticals	4.70%
SXTC China SXT Pharmaceuticals	3.95%
TFFP TFF Pharmaceuticals	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
HEPA Hepion Pharmaceuticals	20	10.98 million	6.63 million	No Data
SXTC China SXT Pharmaceuticals	90	15.83 million	3.90 million	Not Optionable
TFFP TFF Pharmaceuticals	19	4.44 million	4.24 million	Optionable

TFFP, SXTC, HEPA, and EVFM Headlines

Recent News About These Companies

TFF Pharmaceuticals approves dissolution plan

March 8, 2025 | uk.investing.com

TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

February 6, 2025 | prnewswire.com

TFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True Potential

December 12, 2024 | bovnews.com

The TFFP Stock Mystery: Why Did TFFP Plunge Today?

December 6, 2024 | bovnews.com

TFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?

November 23, 2024 | bovnews.com

Stock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?

November 20, 2024 | bovnews.com

TFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock Movements

November 19, 2024 | bovnews.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%

November 15, 2024 | msn.com

TFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?

November 15, 2024 | bovnews.com

TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down

November 15, 2024 | marketwatch.com

TFF Pharmaceuticals terminates employees, to wind down operations

November 15, 2024 | markets.businessinsider.com

TFF Pharmaceuticals to Dissolve and Liquidate Assets

November 15, 2024 | markets.businessinsider.com

TFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of Operations

November 14, 2024 | quiverquant.com

TFF Pharmaceuticals Announces It Will Wind Down Operations

November 14, 2024 | globenewswire.com

TFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News Summary

October 9, 2024 | benzinga.com

TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why

October 8, 2024 | zacks.com

TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | finanznachrichten.de

TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

September 26, 2024 | markets.businessinsider.com

Post-COVID Trends in Biopharma Contract Manufacturing

September 25, 2024 | contractpharma.com

The Yadot Group to Acquire Experiential Agency Socials Dallas

September 16, 2024 | dallasinnovates.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TFFP, SXTC, HEPA, and EVFM Company Descriptions

Evofem Biosciences NASDAQ:EVFM

$0.01 +0.00 (+1.01%)

As of 03:03 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Hepion Pharmaceuticals NASDAQ:HEPA

$0.04 +0.00 (+0.50%)

As of 03:36 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.28 -0.04 (-2.65%)

As of 04:00 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

TFF Pharmaceuticals NASDAQ:TFFP

$0.06 0.00 (0.00%)

As of 04/10/2025

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time